Pre-exposure prophylaxis with on-demand versus daily TDF/FTC in men who have sex with men at high risk of HIV infection – a crossover study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800016100

Enrollment

Unknown

Registered

2018-05-11

Start date

2018-07-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV infection

Interventions

Two groups:Truvada tablet (Tenofovir 300 mg / Emtricitabine 200 mg): 1 tablet daily versus 2 tablets before sex, and 1 tablet at 24 and then 48 hours afterwards, for 16 weeks

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. men who have sex with men (MSM); 2. Aged 186. years old or above; 3. able to communicate in written and spoken English or Chinese; 4. inclination to engage in unprotected anal sex; 5. a history of unprotected anal sex, especially as receptive partner, within the preceding 6 months; 6. normally resident in Hong Kong; 7. referral from an HIV counselling service.

Exclusion criteria

Exclusion criteria: 1. prisoner; 2. having any form of mental illnesses; 3. inability or refusal to give consent; 4. HIV positive; 5. known renal insufficiency with creatinine clearance <60mL/min; 6. known hepatitis B carrier.

Design outcomes

Primary

Measure	Time frame
Adherence rate;Coverage of unprotected sex episodes by PrEP;	—

Secondary

Measure	Time frame
Proportion fully adherent to the protocol;Discontinuation rate;Rate of risk compensation;	—

Countries

China

Contacts

Public ContactShui Shan Lee

Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong

sslee@cuhk.edu.hk+852 22528812

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026